Here are the staff publications for January 2024.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 5th February 2024.

1. Bawden EG, Wagner T, Schröder J, Effern M, Hinze D, Newland L, Attrill GH, Lee AR, Engel S, Freestone D, de Lima Moreira M, Gressier E, McBain N, Bachem A, Haque A, Dong R, Ferguson AL, Edwards JJ, Ferguson PM, Scolyer RA, Wilmott JS, Jewell CM, Brooks AG, Gyorki DE, Palendira U, Bedoui S, Waithman J, Hochheiser K, Hölzel M, Gebhardt T. CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol 2024;9:eadi9517.
2. Brown DV, Anttila CJA, Ling L, Grave P, Baldwin TM, Munnings R, Farchione AJ, Bryant VL, Dunstone A, Biben C, Taoudi S, Weber TS, Naik SH, Hadla A, Barker HE, Vandenberg CJ, Dall G, Scott CL, Moore Z, Whittle JR, Freytag S, Best SA, Papenfuss AT, Olechnowicz SWZ, MacRaild SE, Wilcox S, Hickey PF, Amann-Zalcenstein D, Bowden R. A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq. Genomics 2024;116:110793.
3. Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia-Manero G, Vey N, Wermke M, Janssen J, Narayan R, Fleming S, Loo S, Tovar N, Kontro M, Ottmann OG, Naidu P, Sun H, Han M, White R, Zhang N, Mohammed A, Sabatos-Peyton CA, Steensma DP, Rinne ML, Borate UM, Wei AH. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol 2024;99:E32-E6.
4. Dax V, Ftanou M, Tran B, Lewin J, Wiley JF. Malignancy, masculinities, and psychological distress: Comparisons made between men with testicular cancer and healthy controls. Psychooncology 2024;33:e6262.
5. Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH, Jr., Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Investigator GO, Study G, Han SW. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med 2024;30:271-8.
6. Diamond Y, Gilsenan M, Wang SS, Hanna D, Conyers R, Cole T, Hughes D, Fleming J, Meyran D, Toro C, Malalasekera V, Khaw SL, Haeusler GM. Infections in children following chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia. Transpl Infect Dis 2023;25:e14202.
7. Dinevska M, Widodo SS, Cook L, Stylli SS, Ramsay RG, Mantamadiotis T. CREB: A multifaceted transcriptional regulator of neural and immune function in CNS tumors. Brain Behav Immun 2024;116:140-9.
8. Douglas AP, Slavin MA. Extended duration of letermovir prophylaxis: how long is long enough? Lancet Haematol 2024;11:e88-e90.
9. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024;390:118-31.
10. Eppler M, Ganjavi C, Ramacciotti LS, Piazza P, Rodler S, Checcucci E, Gomez Rivas J, Kowalewski KF, Belenchon IR, Puliatti S, Taratkin M, Veccia A, Baekelandt L, Teoh JY, Somani BK, Wroclawski M, Abreu A, Porpiglia F, Gill IS, Murphy DG, Canes D, Cacciamani GE. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol 2024;85:146-53.
11. Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro GI, ElNaggar AC, Panni S, Ravichandran V, Frazier AL, DiPrimeo D, Eli LD, Solit DB. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecol Oncol 2024;181:162-9.
12. Gaudreault M, Chang D, Kron T, Siva S, Chander S, Hardcastle N, Yeo A. Development of an automated treatment planning approach for lattice radiation therapy. Med Phys 2024;51:682-93.
13. Gearing PF, Devine M, Edmondson MJ, Concannon E, Sheikh R. Reconstruction of a Large Extramammary Paget Disease Pelvic Defect. Dermatol Surg 2024;50:183-5.
14. Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, M JW. The role of aberrant DNA methylation in cancer initiation and clinical impacts. Ther Adv Med Oncol 2024;16:17588359231220511.
15. Goh W, Sudholz H, Foroutan M, Scheer S, Pfefferle A, Delconte RB, Meng X, Shen Z, Hennessey R, Kong IY, Schuster IS, Andoniou CE, Davis MJ, Hediyeh-Zadeh S, Souza-Fonseca-Guimaraes F, Parish IA, Beavis P, Thiele D, Chopin M, Degli-Esposti MA, Cursons J, Kallies A, Rautela J, Nutt SL, Huntington ND. IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development. Nat Immunol 2024;25:240-55.
16. Gore C, Lisy K, O'Callaghan C, Wood C, Emery J, Martin A, De Abreu Lourenco R, Schofield P, Jefford M. Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: A qualitative study. Psychooncology 2024;33:e6265.
17. Haeusler GM, Styczynski J, Zimmer AJ. Shifting landscape of infectious diseases in hematologic malignancies: A hematopoietic cell transplantation and cellular therapy special edition. Transpl Infect Dis 2023;25 Suppl 1:e14195.
18. Hardcastle SJ, Maxwell-Smith C, Cavalheri V, Boyle T, Roman ML, Platell C, Levitt M, Saunders C, Sardelic F, Nightingale S, McCormick J, Lynch C, Cohen PA, Bulsara M, Hince D. A randomized controlled trial of Promoting Physical Activity in Regional and Remote Cancer Survivors (PPARCS). J Sport Health Sci 2024;13:81-9.
19. Heynemann S, Lipworth W, McLachlan SA, Philip J, John T, Kerridge I. Therapeutic misunderstandings in modern research. Bioethics 2024;38:138-52.
20. Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther 2024;30:77 e1- e15.
21. Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur J Cancer 2024;199:113563.
22. Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, Eckert K, Cheung LWK, Mukherjee A, Dean JP, Szafer-Glusman E, Seymour JF. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res 2024;30:498-505.
23. Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jadersten M, Russell N, Dillon R. Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML. Blood Adv 2024;8:343-52.
24. Kelly R, Guo C, Desai J, Tran B. Changing trends in phase 1 oncology clinical trials. Contemp Clin Trials Commun 2024;37:101239.
25. Khanina A, Rozova V, Elkins S, Verspoor K, Thursky K. Designing a Digital Health Solution: A Platform for Automated Surveillance of Fungal Infection. Stud Health Technol Inform 2024;310:1454-5.
26. Ko HS. Advancing radiomics research translation through a public database. Eur Radiol 2024;34:433-5.
27. Ko HS, Denehy L, Edbrooke L, Albarqouni S, Attenberger U, Parker BL, Cox A, Le B, Cheng L. Enhancing oncological care: A guide to setting up a new multidisciplinary cancer cachexia clinic within a tertiary centre. J Cachexia Sarcopenia Muscle 2024;15:4-7.
28. Kroeger B, Manning SA, Fonseka Y, Oorschot V, Crawford SA, Ramm G, Harvey KF. Basal spot junctions of Drosophila epithelial tissues respond to morphogenetic forces and regulate Hippo signaling. Dev Cell 2024;59:262-79 e6.
29. Lee RG, Rudler DL, Raven SA, Peng L, Chopin A, Moh ESX, McCubbin T, Siira SJ, Fagan SV, DeBono NJ, Stentenbach M, Browne J, Rackham FF, Li J, Simpson KJ, Marcellin E, Packer NH, Reid GE, Padman BS, Rackham O, Filipovska A. Quantitative subcellular reconstruction reveals a lipid mediated inter-organelle biogenesis network. Nat Cell Biol 2024;26:57-71.
30. Livingston PM, Winter N, Ugalde A, Orellana L, Mikocka-Walus A, Jefford M, Zalcberg J, Orford N, Hutchinson AM, Barbour A, Kiss N, Smithers BM, Watson DI, McCaffrey N, White V. iCare - a self-directed, interactive online program to improve health and wellbeing for people living with upper gastrointestinal or hepato-pancreato-biliary cancers, and their informal carers: the study protocol for a Phase II randomised controlled trial. BMC Cancer 2024;24:144.
31. Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, Goranitis I, Peters R, Savulescu J, Lunke S, Stark Z, Vears DF. Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. Int J Neonatal Screen 2024;10.
32. McLean L, Curtis K, Hodges J, King L, Wuellner L, Zheng A, Rushton S, O'Brien T. Enhancing Clinical Safety and Cancer Patient Experience Through Comprehensive eLearning on Central Venous Access Devices. Stud Health Technol Inform 2024;310:1394-5.
33. McLean LS, Lim AM, Bressel M, Lee J, Ladwa R, Guminski AD, Hughes B, Bowyer S, Briscoe K, Harris S, Kukard C, Zielinski R, Alamgeer M, Carlino M, Mo J, Park JJ, Khattak MA, Day F, Rischin D. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Med J Aust 2024;220:80-90.
34. McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase DK, Filshie R, Firkin F, Lacaze P, Mason K, Mills AK, Pepperell D, Patil S, Stevenson W, Szer J, Waters N, Wilson K, Ting S, Wood E. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open 2024;14:e076246.
35. Montico B, Nigro A, Lamberti MJ, Martorelli D, Mastorci K, Ravo M, Giurato G, Steffan A, Dolcetti R, Casolaro V, Dal Col J. Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell-based vaccine efficiency to elicit antitumor immune response in vitro. Cytotherapy 2024;26:145-56.
36. Mun Chow K, Zheng So W, Jie Lee H, Lee A, Wei Ting Yap D, Takwoingi Y, Jack Tay K, Tuan J, Ping Thang S, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K. Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis" [Eur. Urol. 84(1) (2023) 36-48]. Eur Urol 2024;85:e60-e1.
37. Ng MF, Da Silva Viana J, Tan PJ, Britto DD, Choi SB, Kobayashi S, Samat N, Song DSS, Ogawa S, Parhar IS, Astin JW, Hogan BM, Patel V, Okuda KS. Canthin-6-One Inhibits Developmental and Tumour-Associated Angiogenesis in Zebrafish. Pharmaceuticals (Basel) 2024;17.
38. Odutola MK, van Leeuwen MT, Bruinsma F, Turner J, Hertzberg M, Seymour JF, Prince HM, Trotman J, Verner E, Roncolato F, Opat S, Lindeman R, Tiley C, Milliken ST, Underhill CR, Benke G, Giles GG, Vajdic CM. A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk. Cancer Epidemiol Biomarkers Prev 2024;33:106-16.
39. Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif AL, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar R, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 2024;143:336-41.
40. Paloja K, Weiden J, Hellmeier J, Eklund AS, Reinhardt SCM, Parish IA, Jungmann R, Bastings MMC. Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint. ACS Nano 2024;18:1381-95.
41. Pham TD, Larach T, Othman B, Rajkomar A, Heriot AG, Warrier SK, Smart P. Robotic natural orifice specimen extraction surgery (NOSES) for anterior resection. Ann Coloproctol 2023;39:526-30.
42. Pounraj S, Chen S, Ma L, Mazzieri R, Dolcetti R, Rehm BHA. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines. Cancer Res 2024;84:353-63.
43. Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol 2024;35:29-65.
44. 44.  Rees MJ, Rivalland A, Tan S, Xie M, Yong MK, Ritchie D. Non-viral pathogens of infectious diarrhoea post-allogeneic stem cell t       ransplantation are associated with graft-versus-host disease. Ann Hematol 2024;103:593-602.
45. Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Dieras V. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future Oncol 2024;20:5-16.
46. Ruparelia AA, Salavaty A, Barlow CK, Lu Y, Sonntag C, Hersey L, Eramo MJ, Krug J, Reuter H, Schittenhelm RB, Ramialison M, Cox A, Ryan MT, Creek DJ, Englert C, Currie PD. The African killifish: A short-lived vertebrate model to study the biology of sarcopenia and longevity. Aging Cell 2024;23:e13862.
47. Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. Eur J Cancer 2024;200:113535.
48. Ryan J, Hardcastle N, Francis R, Ferjančič P, Ng SP, Koh ES, Geso M, Kelly J, Ebert MA. The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma. Phys Imaging Radiat Oncol 2024;29:100536.
49. Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. Eur Urol Oncol 2024;7:27-43.
50. Storek J, Lindsay J. Rituximab for posttransplant lymphoproliferative disorder - therapeutic, preemptive, or prophylactic? Bone Marrow Transplant 2024;59:6-11.
51. Thompson EJ, Escarbe S, Tvorogov D, Farshid G, Gregory PA, Khew-Goodall Y, Madden S, Ingman WV, Lindeman GJ, Lim E, Lopez AF, Bonder CS. Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis. Growth Factors 2024:1-13.
52. Trubiano JA, Vogrin S, Douglas AP, Chua KYL. Reply to Olans and Olans. Clin Infect Dis 2024;78:227-8.
53. Udovicich C, Perera M, Hofman MS, Siva S. FAPI PET/CT: a new kid on the block for RCC. Eur J Nucl Med Mol Imaging 2024;51:862-3.
54. Wang Y, Dackus G, Rosenberg EH, Cornelissen S, de Boo LW, Broeks A, Brugman W, Chan TWS, van Diest PJ, Hauptmann M, Ter Hoeve ND, Isaeva OI, de Jong VMT, Jóźwiak K, Kluin RJC, Kok M, Koop E, Nederlof PM, Opdam M, Schouten PC, Siesling S, van Steenis C, Voogd AC, Vreuls W, Salgado RF, Linn SC, Schmidt MK. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status. BMC Med 2024;22:9.
55. Watson E, Rajkhowa A, Dunt D, Bull A, Worth LJ, Bennett N. Evaluation of an Infection surveillance program in residential aged care facilities in Victoria, Australia. BMC Public Health 2024;24:254.
56. Young RJ, Angel C, Bressel M, Pizzolla A, Thai AA, Porceddu SV, Liu H, Idrizi R, Metta J, Lim AM, Solomon BJ, Rischin D. Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer. Oral Oncol 2024;150:106687.
57. Zhou C, Solomon B, Pérol M. Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply. N Engl J Med 2024;390:381-2.